News & Events – Page 18 – Sumitovant

Select Company

June 06, 2019Urovant Sciences to Report Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
June 05, 2019Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia
June 04, 2019Myovant Sciences to Present at Upcoming June Investor Conferences
June 03, 2019Urovant Sciences to Present at Annual Roivant Pipeline Day
May 30, 2019Urovant Sciences to Present at the Jefferies 2019 Healthcare Conference
May 30, 2019Myovant Sciences Announces Pricing of $125 Million Public Offering of Common Shares
May 29, 2019Myovant Sciences Announces $100 Million Public Offering of Common Shares
May 24, 2019Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
May 14, 2019Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
May 13, 2019Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
« Previous 1 … 16 17 18 19 20 21 Next »